Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | CDK8 | P49336 | 3/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | LTK | P29376 | 2/20 | 0.33 |
| ▸ | GRK5 | P34947 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840962 | 0.74 | LRRK2 (0.39) | CHEK1LRRK2CDK8DAPK3PRKD3 | |
| SCHEMBL23989198 | 0.70 | CHEK1 (0.33) | NNMTCHEK1LRRK2CDK8DAPK3 | |
| SCHEMBL2600505 | 0.70 | ROCK2 (0.36) | NNMTROCK1UHRF1 | |
| SCHEMBL23629867 | 0.69 | CHEK1 (0.33) | CHEK1LRRK2CDK8MAP2K1CAMK2A | |
| SCHEMBL28552432 | 0.69 | CHEK1 (0.33) | CHEK1LRRK2CDK8MAP2K1CAMK2A | |
| SCHEMBL27270934 | 0.67 | NNMT (0.33) | NNMT | |
| SCHEMBL14102232 | 0.67 | NNMT (0.33) | NNMTUHRF1 | |
| SCHEMBL29799324 | 0.66 | NNMT (0.50) | NNMTCHEK1LRRK2CDK8DAPK3 | |
| SCHEMBL1553765 | 0.66 | NNMT (0.50) | NNMTCHEK1LRRK2CDK8DAPK3 | |
| SCHEMBL17362743 | 0.65 | KDR (0.47) | NNMTCHEK1LRRK2CDK8DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-115209921-B | Antibody drug conjugates comprising cyclic dinucleotide derivatives | 第一三共株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | disclosed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | disclosed |
| CN-115209921-A | Antibody drug conjugates comprising novel cyclic dinucleotide derivatives | 第一三共株式会社 | 2022-10-18 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | NNMT 1144/4885CHEK1 819/4885LRRK2 1186/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | NNMT 1490/4885CHEK1 784/4885LRRK2 1164/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | NNMT 1490/4885CHEK1 784/4885LRRK2 1164/4885 |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, CGAS, TLR9 | NNMT 512/4885CHEK1 1797/4885LRRK2 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.